IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Chen, Miao Fen ^a,b   Chen, Ping Tsung ^a,b   Lu, Ming Shian ^a   Lin, Paul Yang ^a   Chen, Wen Cheng ^a,b   Lee, Kuan Der ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

IL 6, Esophageal squamous cell carcinoma; Prognosis

Indexed keywords

INTERLEUKIN 6; STAT3 PROTEIN;

ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURVIVAL; CELL DEATH; CONTROLLED STUDY; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RADIOSENSITIVITY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION; HUMANS; INTERLEUKIN-6; MICE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 84875821295     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-26     Document Type: Article

References (39)

1. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009, 27:5062-7. 10.1200/JCO.2009.22.2083, 19770374.
2. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011, 12:681-92. 10.1016/S1470-2045(11)70142-5, 21684205.
3. Pottgen C, Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer-a meta-analysis of the randomized trials. Cancer Treat Rev 2012, 38:599-604. 10.1016/j.ctrv.2011.10.005, 22116018.
4. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420:860-7. 10.1038/nature01322, 2803035, 12490959.
5. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004, 202:275-93. 10.1111/j.0105-2896.2004.00199.x, 15546400.
6. Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. J Clin Invest 2007, 117:3660-3. 10.1172/JCI34237, 2096452, 18060028.
7. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993, 54:1-78.
8. Chen CC, Chen WC, Lu CH, Wang WH, Lin PY, Lee KD. Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor. Int J Radiat Oncol Biol Phys 2010, 76:1214-24. 10.1016/j.ijrobp.2009.09.059, 20206020.
9. Santer FR, Malinowska K, Culig Z, Cavarretta IT. Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer 2010, 17:241-53. 10.1677/ERC-09-0200, 2829126, 19966016.
10. George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 2005, 11:1815-20. 10.1158/1078-0432.CCR-04-1560, 15756004.
11. Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Iizuka N. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 1996, 56:2776-80.
12. Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 1995, 71:354-6. 10.1038/bjc.1995.71, 2033591, 7841052.
13. Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, Kim BG. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 2009, 9:155. 10.1186/1471-2407-9-155, 2694817, 19457231.
14. Lukaszewicz-Zajac M, Mroczko B, Kozlowski M, Niklinski J, Laudanski J, Szmitkowski M. Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients. Dis Esophagus 2012, 25:242-9. 10.1111/j.1442-2050.2011.01242.x, 21895853.
15. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer 2006, 106:552-8. 10.1002/cncr.21601, 16353210.
16. Lee CH, Wu DC, Lee JM, Wu IC, Goan YG, Kao EL. Anatomical subsite discrepancy in relation to the impact of the consumption of alcohol, tobacco and betel quid on esophageal cancer. Int J Cancer 2007, 120:1755-62. 10.1002/ijc.22324, 17230518.
17. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009, 28:335-44. 10.1007/s10555-009-9194-7, 20012924.
18. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002, 109:1139-42. 150969, 11994401.
19. Chen MF, Lu MS, Lin PY, Chen PT, Chen WC, Lee KD. The role of DNA methyltransferase 3b in esophageal squamous cell carcinoma. Cancer 2012, 118:4074-89. 10.1002/cncr.26736, 22213175.
20. Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011, 30:83-95. 10.1007/s10555-011-9281-4, 21249423.
21. Sharma S, Sharma MC, Sarkar C. Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology 2005, 46:481-9. 10.1111/j.1365-2559.2005.02142.x, 15842629.
22. Kuonen F, Secondini C, Ruegg C, Molecular Pathways Emerging pathways mediating growth, invasion and metastasis of tumors progressing in an irradiated microenvironment. Clin Cancer Res 2012, 18:5196-202. 10.1158/1078-0432.CCR-11-1758, 22730447, Molecular Pathways.
23. Stahl M. Is there any role for surgery in the multidisciplinary treatment of esophageal cancer?. Ann Oncol 2010, 21(Suppl 7):vii283-5.
24. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012, 38:904-10. 10.1016/j.ctrv.2012.04.007, 22651903.
25. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-79. 10.1038/sj.onc.1206933, 14576837.
26. Suchi K, Fujiwara H, Okamura S, Okamura H, Umehara S, Todo M. Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells. Anticancer Res 2011, 31:67-75.
27. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003, 9:4653-65. 2929399, 14581334.
28. Leu CM, Wong FH, Chang C, Huang SF, Hu CP. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 2003, 22:7809-18. 10.1038/sj.onc.1207084, 14586407.
29. Chen MF, Lee KD, Lu MS, Chen CC, Hsieh MJ, Liu YH. The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma. J Mol Med (Berl) 2009, 87:307-20.
30. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-54. 10.1038/nrc822, 12189386.
31. Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Foisner R, Beug H. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res 2004, 566:9-20. 10.1016/S1383-5742(03)00033-4, 14706509.
32. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C. Stat3 as an oncogene. Cell 1999, 98:295-303. 10.1016/S0092-8674(00)81959-5, 10458605.
33. Levy DE, Darnell JE. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002, 3:651-62.
34. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007, 282:20059-63. 10.1074/jbc.R700016200, 17502367.
35. Aggarwal BB A, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci 2009, 1171:59-76. 10.1111/j.1749-6632.2009.04911.x, 3141289, 19723038.
36. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005, 5:231-7. 10.1038/nrc1560, 15738985.
37. Olive PL, Banath JP. Phosphorylation of histone H2AX as a measure of radiosensitivity. Int J Radiat Oncol Biol Phys 2004, 58:331-5. 10.1016/j.ijrobp.2003.09.028, 14751500.
38. Oshima Y, Yajima S, Yamazaki K, Matsushita K, Tagawa M, Shimada H. Angiogenesis-related factors are molecular targets for diagnosis and treatment of patients with esophageal carcinoma. Ann Thorac Cardiovasc Surg 2010, 16:389-93.
39. Kozin SV, Duda DG, Munn LL, Jain RK. Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors?. J Natl Cancer Inst 2012, 104:899-905. 10.1093/jnci/djs239, 22572994.